Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
| العنوان: | Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients |
|---|---|
| المؤلفون: | Paiva, Bruno, Cedena, Maria-Teresa, Puig, Noemi, Arana, Paula, Vidriales, Maria-Belen, Cordon, Lourdes, Flores-Montero, Juan, Gutierrez, Norma C, Martín-Ramos, María-Luisa, Martinez-Lopez, Joaquin, Ocio, Enrique M, Hernandez, Miguel T, Teruel, Ana-Isabel, Rosiñol, Laura, Echeveste, María-Asunción, Martinez, Rafael, Gironella, Mercedes, Oriol, Albert, Cabrera, Carmen, Martin, Jesus, Bargay, Joan, Encinas, Cristina, Gonzalez, Yolanda, Van Dongen, Jacques J M, Orfao, Alberto, Bladé, Joan, Mateos, Maria-Victoria, Lahuerta, Juan José, San Miguel, Jesús F, Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups |
| المساهمون: | Instituto de Salud Carlos III, Red Temática de Investigación Cooperativa en Cáncer (España), Asociación Española Contra el Cáncer, International Myeloma Foundation, European Research Council, Immunology |
| المصدر: | BLOOD r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname Blood r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe Digital.CSIC. Repositorio Institucional del CSIC Blood, 127(25), 3165-3174. American Society of Hematology |
| بيانات النشر: | AMER SOC HEMATOLOGY, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Male, Oncology, Pediatrics, Neoplasm, Residual, Biochemistry, Biomarkers, Pharmacological, Dexamethasone, law.invention, 0302 clinical medicine, Randomized controlled trial, law, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Medicine, Lenalidomide, Melphalan, Multiple myeloma, Aged, 80 and over, Hematology, Prognosis, Thalidomide, 3. Good health, Vincristine, 030220 oncology & carcinogenesis, Female, Drug Monitoring, Multiple Myeloma, medicine.drug, medicine.medical_specialty, Immunology, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, Humans, Survival analysis, Aged, Monitoring, Physiologic, business.industry, Immunity, Cell Biology, medicine.disease, Survival Analysis, Minimal residual disease, Clinical trial, Transplantation, body regions, Concomitant, Prednisone, business, 030215 immunology |
| الوصف: | The value of minimal residual disease (MRD) in multiple myeloma (MM) has been more frequently investigated in transplant-eligible patients than in elderly patients. Because an optimal balance between treatment efficacy and toxicity is of utmost importance in patients with elderly MM, sensitive MRD monitoring might be particularly valuable in this patient population. Here, we used second-generation 8-color multiparameter-flow cytometry (MFC) to monitor MRD in 162 transplant-ineligible MM patients enrolled in the PETHEMA/GEM2010MAS65 study. The transition from first- to second-generation MFC resulted in increased sensitivity and allowed us to identify 3 patient groups according to MRD levels: MRD negative (75 years (HR, 4.8; P < .001), as well as those with high-risk cytogenetics (HR, 12.6; P = .01). Using second-generation MFC, immune profiling concomitant to MRD monitoring also contributed to identify patients with poor, intermediate, and favorable outcomes (25%, 61%, and 100% OS at 3 years, respectively; P = .01), the later patients being characterized by an increased compartment of mature B cells. Our results show that similarly to transplant candidates, MRD monitoring is one of the most relevant prognostic factors in elderly MM patients, irrespectively of age or cytogenetic risk. This study was supported by Cooperative Research Thematic Network grants RD12/0036/0058, RD12/0036/0048, RD12/0036/0046, and RD12/0036/0061 of the Red de Cancer (Cancer Network of Excellence); Instituto de Salud Carlos III, Spain, Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS: PI060339; 06/1354; 02/0905; 01/0089/01-02; PS09/01897/01370; PI13/01469, PI14/01867, G03/136; Sara Borrell: CD13/00340 and CD12/00540); and Asociación Española Contra el Cáncer (GCB120981SAN). The study was also supported internationally by the Black Swan Research Initiative of the International Myeloma Foundation and a European Research Council 2015 starting grant. |
| تدمد: | 0006-4971 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e53803bf8a168a0aefd84e3ef3c57fecTest https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=3240Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e53803bf8a168a0aefd84e3ef3c57fec |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00064971 |
|---|